ARTICLE | Clinical News
[18F]-fluciclovine regulatory update
December 21, 2015 8:00 AM UTC
FDA accepted and granted Priority Review to an NDA from Blue Earth for [18F]-fluciclovine PET imaging agent to detect and localize recurrent prostate cancer lesions. The company declined to disclose ...